The Associated Press

LONDON – PLC (NYSE: GSK) says it has finalized a deal to sell its research operations in Italy to Aptuit Inc.

GSK hasn’t revealed financial terms for the deal disclosed on Thursday. Some 500 staff at a facility in Verona will be transferred from Glaxo to Aptuit.

The London-based drug maker will also continue to receive research & development services from Aptuit.

GSK had announced in February that it planned to stop discovery research in select neurosciences areas such as pain and depression – impacting on research at the Italian facility.

GSK operates its North American headquarters in Research Triangle Park.

Get the latest news alerts: at Twitter.